ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301
08 oct. 2024 08h00 HE | ImmuneSensor Therapeutics
DALLAS, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists targeting...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
17 sept. 2024 08h00 HE | ImmuneSensor Therapeutics
Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual Biotechnology Private Company Symposium
16 sept. 2024 16h00 HE | ImmuneSensor Therapeutics
DALLAS, Sept. 16, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19 août 2024 08h00 HE | ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
01 mai 2024 08h00 HE | ImmuneSensor Therapeutics
DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...